Related Experiment Video
Updated: May 5, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
Predicting Treatment of Bioprosthetic Aortic Valve Failure in the United States: A Proposed Model
Philippe Généreux1, Martin B Leon2,3, Roy D Dar4
1Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey.
Abstract:
•Transcatheter aortic valve replacement (TAVR) is the dominant treatment for aortic stenosis; the need to treat TAVR failure is increasing.•TAVR valve-in-valve (ViV) is predicted to reach ∼42,000 procedures by 2035.•TAVR ViV will represent ∼15% of all TAVR performed by 2035.•TAVR-in-TAVR will match TAVR-in-surgical aortic valve replacement by 2028 and dominate thereafter.•To ensure the viability of TAVR ViV, the use of leaflet modification is needed.
More Related Videos
14:14Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
Published on: December 11, 2017
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022